Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
Microvasc Res. 2010 May;79(3):224-8. doi: 10.1016/j.mvr.2010.02.007. Epub 2010 Feb 20.
Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) play a different role in cancer development, acting as possible markers of vascular turnover/damage (CECs) and vasculogenesis (CEPs). Preclinical and clinical data suggest that CEC enumeration might be useful to define the best treatment option for patients who are candidate to anti-angiogenic therapy, while CEPs seem to have a "catalytic" role in different steps of cancer progression and recurrence after therapy. The definition of CEC and CEP phenotype and the standardization of CEC and CEP enumeration procedures are highly warranted to use these cells as biomarkers in clinical trials in oncology, and to compare results from different studies.
循环内皮细胞 (CECs) 和循环内皮祖细胞 (CEPs) 在癌症发展中发挥不同的作用，它们分别作为血管生成/损伤的标志物 (CECs) 和血管发生的标志物 (CEPs)。临床前和临床数据表明，CEC 的计数可能有助于为接受抗血管生成治疗的患者确定最佳治疗方案，而 CEPs 在癌症进展和治疗后复发的不同阶段似乎具有“催化”作用。因此，强烈需要定义 CEC 和 CEP 的表型，并规范 CEC 和 CEP 计数程序，以便将这些细胞作为肿瘤学临床试验中的生物标志物，并比较不同研究的结果。
